Dyadic International (NASDAQ:DYAI) Stock Crosses Below 50-Day Moving Average – Time to Sell?

Dyadic International Inc. (NASDAQ:DYAI)’s stock price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.94 and traded as low as $0.85. Dyadic International shares last traded at $0.89, with a volume of 33,590 shares traded.

Analysts Set New Price Targets

Several equities research analysts have recently commented on DYAI shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a research note on Monday, December 29th. HC Wainwright initiated coverage on Dyadic International in a research note on Thursday, October 23rd. They issued a “buy” rating and a $3.00 target price for the company. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $3.00.

Dyadic International Stock Performance

The company has a current ratio of 2.85, a quick ratio of 2.85 and a debt-to-equity ratio of 1.92. The firm’s fifty day moving average is $0.93 and its 200 day moving average is $0.99. The company has a market cap of $31.49 million, a PE ratio of -3.63 and a beta of 1.26.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Dyadic International had a negative return on equity of 537.31% and a negative net margin of 221.09%.The business had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.22 million. As a group, research analysts predict that Dyadic International Inc. will post -0.18 EPS for the current fiscal year.

Institutional Investors Weigh In On Dyadic International

A number of hedge funds have recently added to or reduced their stakes in DYAI. Apis Capital Advisors LLC purchased a new position in shares of Dyadic International in the 3rd quarter valued at $1,817,000. Chapin Davis Inc. raised its position in Dyadic International by 5.6% in the third quarter. Chapin Davis Inc. now owns 932,004 shares of the biotechnology company’s stock worth $1,100,000 after acquiring an additional 49,155 shares in the last quarter. Perkins Capital Management Inc. boosted its position in shares of Dyadic International by 627.4% during the 3rd quarter. Perkins Capital Management Inc. now owns 348,050 shares of the biotechnology company’s stock worth $411,000 after purchasing an additional 300,200 shares in the last quarter. Truist Financial Corp grew its stake in shares of Dyadic International by 30.5% during the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock worth $385,000 after purchasing an additional 76,200 shares during the period. Finally, Landscape Capital Management L.L.C. purchased a new position in shares of Dyadic International in the 3rd quarter valued at about $190,000. 27.95% of the stock is currently owned by institutional investors and hedge funds.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.